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Background/Aims: The influence of hepatic steatosis (HS) on chronic hepatitis B (CHB) is unclear. We evaluated the 
influence of the degree of HS, assessed using the controlled attenuation parameter (CAP) of transient elastography (TE), 
on treatment outcomes in CHB patients initiated on antiviral therapy.
Methods: A total of 334 patients who were initiated on entecavir or tenofovir between 2007 and 2016 with available TE 
results were recruited.
Results: Of the total study population, 146 (43.7%) patients had HS (CAP >238 dB/m). Three-hundred-three patients 
(90.7%) achieved complete virological response (CVR) (hepatitis B virus DNA <12 IU/L), and 25 patients (7.5%) developed 
hepatocellular carcinoma (HCC). Among hepatitis B e antigen (HBeAg)-positive patients (n=172, 51.5%), 37 (21.5%) 
experienced HBeAg loss. On univariate analysis, CAP value was not associated with the probability of HCC development 
(P=0.380). However, lower CAP value was independently associated with higher probability of HBeAg loss among 
HBeAg-positive patients (hazard ratio [HR]=0.991, P=0.026) and with CVR achievement in the entire study population 
(HR=0.996, P=0.004). The cumulative incidence of HBeAg loss among HBeAg-positive patients was significantly higher in 
patients without HS than in those with HS (log-rank, P=0.022).
Conclusions: CAP values were not correlated with HCC development in patients initiated on entecavir and tenofovir. 
However, CAP values were negatively correlated with the probability of HBeAg loss among HBeAg-positive patients and 
with CVR achievement. (Clin Mol Hepatol 2019;25:283-293)
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Study Highlights
• There is a lack of evidence to support the influence of hepatic steatosis (HS) on antiviral therapy with entecavir and tenofovir.
• The controlled attenuation parameter (CAP) values, measured by transient elastography, can assess the degree of HS.
• CAP values were negatively correlated with the probability of hepatitis B e antigen (HBeAg) loss among HBeAg-positive patients.
• CAP values were associated with the achievement of complete virological response, whereas they were not associated with the risk of develop-
ing hepatocellular carcinoma.
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IntroduCtIon
More than 250 million people are infected with hepatitis B virus 
(HBV) worldwide, including >6% of the Asian and Western Pacific 
adult population.1 Additionally, more than 20% of patients with 
chronic hepatitis B (CHB) developed hepatocellular carcinoma 
(HCC) within 10 years.2,3 Thus, to prevent poor outcomes in pa-
tients with HBV viremia due to uncontrolled replication, the pri-
mary treatment strategy is to suppress replication with antiviral 
therapy (AVT).4 Furthermore, newer AVT agents such as entecavir 
and tenofovir, with little to no resistance, introduce new methods 
of blocking HBV replication.5
Hepatic steatosis (HS) is frequently found in patients with 
chronic liver disease and its prevalence in HBV infected patients 
was reported to be between 14% and 67%.6 However, the influ-
ence of HS on HBV infection has been controversial. First, no as-
sociation between HS and HBV has been reported. Some studies 
showed no significant correlation between the presence of hepa-
titis B e antigen (HBeAg) and HS7,8 and between HBV DNA level 
and HS in genotypes B and C HBV.9 Moreover, a recent study 
demonstrated that HS diagnosed with sonography showed no 
significant correlation with virological response or HBeAg sero-
conversion in CHB patients treated with entecavir.10 In contrast, 
pooled data from seven studies showed a strong protective influ-
ence of HS on HBV viral load.11 The unfavorable influence of HS on 
the clinical outcomes of patients with HBV infection has been also 
reported. Recent studies strongly suggested that severe HS is as-
sociated with severe fibrosis in HBV infection12,13 and that HS low-
ered the efficacy of AVT.10 Furthermore, a previous study showed 
that the presence of metabolic syndrome, which is closely corre-
lated with HS, was an independent risk factor linked with an in-
creased risk of liver cirrhosis and HCC in CHB patients.6,14
Liver biopsy is considered the gold standard for evaluating HS.15 
However, this process cannot be sufficiently used repetitively and 
its value as a screening method is limited by its drawbacks rang-
ing from invasiveness to sampling errors.16 As a noninvasive tool 
for HS diagnosis, ultrasonography is commonly used; however, it 
has limitations such as observer variability and low sensitivity of 
mild HS.17 Recently, transient elastography (TE), equipped with a 
controlled attenuation parameter (CAP), is a proven effective 
method for determining the degree of HS and fibrosis simultane-
ously. The accuracy of CAP in detecting HS has been considered 
acceptable.18
Thus, because it is not yet confirmed whether HS can influence 
the outcome of AVT, we aimed to evaluate the influence of HS, 
assessed using CAP, on the treatment outcomes in CHB patients 
initiated on AVT using entecavir and tenofovir.
MAterIAlS And MetHodS
Between 2007 and 2016, treatment-naïve CHB patients with 
available TE results who were initiated on AVT with entecavir or 
tenofovir, from the database of Severance Hospital, Yonsei Uni-
versity College of Medicine, Seoul, South Korea, were considered 
eligible for this retrospective study. CHB was defined as the per-
sistent presence of serum HBV surface antigen for >6 months. 
The exclusion criteria were as follows: liver stiffness (LS) measure-
ment failure; unreliable LS value; >1 month interval between AVT 
initiation and TE assessment; HCC at enrollment or history of 
HCC; hepatic decompensation or liver transplantation at enroll-
ment, or history of either condition; Child-Pugh class B or C; ala-
nine aminotransferase (ALT) >5× the upper normal limit; co-infec-
tion with human immunodeficiency virus or hepatitis C virus; 
alcohol ingestion in excess of 40 g/day for >5 years; right-sided 
heart failure; ascites or pregnancy; any other serious medical co-
morbidities; or follow-up duration <12 months.
The study methodology conforms to the ethical guidelines of 
the Declaration of Helsinki and was approved by the institutional 
review board of Severance Hospital. Informed consent was waived 
owing to the retrospective nature of the study.
Enrollment and follow-up 
Patients initiated on AVT with either entecavir or tenofovir were 
selected according to our inclusion and exclusion criteria. AVT 
was administered according to the treatment guidelines of the 
Korean Association for the Study of the Liver19 and the reimburse-
ment guidelines of the National Health Insurance Service of the 
Republic of Korea. After AVT initiation, each patient was regularly 
followed up every 3 or 6 months with ultrasound examination and 
laboratory tests. These included tests for the levels of alpha-feto-
protein and virological markers such as HBV DNA and HBeAg and 
anti-HBe antibody. In case of virological breakthrough (defined as 
>1 log IU/mL increase in serum HBV DNA level from nadir on 2 
consecutive tests) or genotypic mutation, rescue therapy was ap-
plied.20
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Fibrosis and steatosis assessment with TE
TE was performed on the right lobe of the liver through the in-
tercostal spaces, with the patient lying down in the dorsal decubi-
tus position with the right arm in maximal abduction. Experienced 
nurses blinded to clinical information performed TE (FibroScan®; 
EchoSens, Paris, France). The results were expressed in kilopascals 
(kPa) for fibrosis and decibels per meter (dB/m) for steatosis. In-
terquartile range (IQR) was used as an index of intrinsic variability 
of TE readings, corresponding to the central interval containing 
50% of valid measurements between the 25th and 75th percen-
tiles. Only examinations with at least 10 validated measurements 
and a success rate of at least 60% and an IQR to median ratio 
<30% for LS were accepted as reliable.15,19 The cutoff LS value for 
significant fibrosis was 13 kPa.21 The cutoff CAP value to diag-
nose the presence of HS was ≥238 dB/m.22
End points and definitions
Complete virological response (CVR), HBeAg loss among 
HBeAg-positive patients, and HCC development were monitored. 
CVR was defined as undetectable HBV DNA level <12 IU/L. 
HBeAg loss was defined as HBeAg negativity among HBeAg-posi-
tive patients at enrollment. HCC diagnosis was based on the 
guidelines of the American Association for the Study of Liver Dis-
eases.23 Liver cirrhosis was diagnosed on the basis of ultrasono-
graphic findings suggestive of cirrhosis, including a blunted, nod-
ular liver edge with splenomegaly (>12 cm).24
Statistical analysis
Continuous variables were expressed as median with IQR, as 
appropriate. When comparing baseline characteristics between 
two groups, a chi-square test (or Fisher’s exact test) and Student’s 
t-test (or Mann-Whitney U-test) were used. Actuarial rates of clini-
cal outcomes were calculated using the Kaplan-Meier method and 
compared with the log-rank test. Independent risk factors for 
each clinical outcome were estimated using multivariate Cox pro-
portional hazard regression analysis. Multivariate analysis was 
performed using variables with a P -value of <0.2 in univariate 
analysis. Statistical analyses were performed using SPSS software 
24.0 (IBM Corp., Armonk, NY, USA), and statistical significance 
was considered for comparisons with a 2-tailed P-value of <0.05.
reSultS
Baseline characteristics
Among 1,658 treatment-naïve patients with CHB who were ini-
tiated on AVT with entecavir or tenofovir between 2007 and 
2016, 476 patients with available TE results were evaluated. 
Twenty-one patients were excluded owing to LS measurement 
failure or unreliable LS value. Of 455 patients with reliable LS val-
ue, 121 were excluded according to our exclusion criteria. Finally, 
334 patients were selected for this retrospective study (Supple-
mentary Fig. 1).
The baseline characteristics of the whole study population are 
described in Table 1. The median age of the study population (210 
men and 124 women) was 51.0 years. HBeAg positivity was found 
in 172 (51.5%) patients, and the median HBV DNA level was 5.84 
log IU/mL. The median CAP value was 229.0 (IQR 202.8–255.0) 
dB/m. Most patients (n=292, 87.4%) received tenofovir.
Comparison between patients with and without HS
Of the study population, 146 (43.7%) patients showed HS (Ta-
ble 1). When patients with and without HS were compared, pa-
tients with HS had significantly higher body mass index (BMI), se-
rum albumin level, platelet count, total cholesterol level, and CAP 
values than those without HS (all P<0.05) However, LS values and 
the proportion of patients with liver cirrhosis (45.9% vs. 51.6%) 
were not significantly different between patients with and with-
out HS (all P>0.05) (Table 1).
Treatment outcomes of AVT
The median follow-up period was 38.6 (IQR 28.1–47.6) months 
(median 38.4 [IQR 28.0–46.7] in patients with HS vs. 38.6 [IQR 
28.1–48.4] months in patients without HS, P=0.757).
The AVT outcomes are listed in Supplementary Table 1. During 
the follow-up period, 303 (90.7%) and 25 (7.5%) patients 
achieved CVR and developed HCC at 5 years, respectively. Among 
172 HBeAg-positive patients, 37 (21.5%) experienced HBeAg 
loss. the proportion of patients with HBeAg loss among HBeAg-
positive patients at 5 years was significantly higher in those with-
out HS (28.3% vs. 13.8%; P=0.022, log-rank test) (Supplementa-
ry Table 1, Fig. 1). 
Among patients treated with entecavir (n=42, 12.6%), the 
probability of HBeAg loss among HBeAg-positive patients was 
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table 1. Baseline characteristics of the study populations
Variables All patients (n=334)
Patients with HS
(n=146, 43.7%)
Patients without HS
(n=188, 56.3%)
P-value
Demographic data
   Age (years) 51.0 (42.8-57.0) 51.0 (42.0-56.3) 51.0 (43.3-57.0) 0.205
   Male gender 210 (62.9) 91 (62.3) 119 (63.3) 0.856
   Body mass index (kg/m2) 23.5 (21.6-25.5) 24.7 (22.3-26.7) 22.5 (20.4-24.4) <0.001
   Diabetes 26 (7.8) 13 (8.9) 13 (6.9) 0.501
Laboratory data
   Total bilirubin (mg/dL) 0.9 (0.7-1.1) 0.8 (0.7-1.1) 0.9 (0.7-1.2) 0.169
   Serum albumin (g/dL) 4.2 (3.9-4.4) 4.2 (4.0-4.4) 4.2 (3.9-4.4) 0.015
   Alanine aminotransferase (IU/L) 56 (35-93) 56 (38-94) 56 (34-90) 0.429
   Platelet count (109/L) 149 (111-195) 167 (116-215) 144 (103-188) 0.003
   Prothrombin time (INR) 1.02 (0.96-1.09) 1.01 (0.97-1.09) 1.03 (0.95-1.10) 0.519
   Total cholesterol (mg/dL) 173 (151-196) 178 (151-204) 170 (151-190) 0.012
   Low-density lipoprotein (mg/dL) 109 (90-127) 113 (93-129) 101 (80-126) 0.293
   Fasting glucose (mg/dL) 95.0 (88.3-104.0) 96.0 (89.3-107.0) 94.0 (87.3-102) 0.040
   Alpha-fetoprotein (ng/mL) 4.7 (2.7-9.6) 4.6 (2.9-9.4) 5.0 (2.5-10.2) 0.100
   HBeAg positivity 172 (51.5) 80 (54.8) 92 (48.9) 0.387
   HBV DNA (log IU/mL) 5.84 (4.48-7.13) 6.10 (4.01-7.21) 5.7 (4.6-7.0) 0.998
Liver cirrhosis 164 (49.1) 67 (45.9) 97 (51.6) 0.301
Transient elastography
   Liver stiffness (kPa) 11.1 (7.1-16.7) 11.6 (7.1-17.0) 10.3 (7.1-16.5) 0.391
   Liver stiffness >13 kPa 132 (39.5) 64 (43.8) 68 (36.2) 0.155
   CAP (dB/m) 229.0 (202.8-255.0) 261 (248-284) 207 (189-223) <0.001
Entecavir/tenofovir 42 (12.6)/292 (87.4) 15 (10.3)/131 (89.7) 27 (14.4)/161 (85.6) 0.264
Variables are expressed as median (interquartile range) or n (%).
HS, hepatic steatosis; INR, international normalized ratio; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; kPa, kilopascal; CAP, controlled 
attenuation parameter; dB/m, decibels per meter.
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Figure 1. Cumulative incidence rates of HBeAg loss (A) (n=172), CVR (B), and HCC (C) (n=334) in patients with and without HS (Kaplan-Meier plot). The 
cumulative incidence rates of HBeAg loss were calculated among HBeAg-positive patients. HBeAg, hepatitis B e antigen; CVR, complete virological re-
sponse; HCC, hepatocellular carcinoma; HS, hepatic steatosis.
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not statistically significant between the groups with and without 
HS (P=0.139, log-rank test), whereas among patients treated with 
tenofovir (n=292, 87.4%), the probability of HBeAg loss was sig-
nificantly higher in the group without HS (P=0.046, log-rank test) 
(Supplementary Fig. 2).
The follow-up period was statistically similar between HBeAg-
positive and HBeAg-negative patients (median 38.7 [IQR 28.3–
48.0] vs. 38.6 [IQR 27.9–47.4] months, P=0.461). In contrast, the 
follow-up duration of patients treated with entecavir and tenofo-
vir was significantly different (median 47.0 [IQR 39.1–59.0] vs. 
36.7 [27.3–46.7] months, P<0.001). When the study population 
was stratified according to HBeAg status, the proportion of pa-
tients with CVR achievement was significantly higher at 5 years 
among HBeAg-negative patients than in HBeAg-positive patients 
(96.3% vs. 85.5%; P<0.001, log-rank test) (Supplementary Table 
2, Supplementary Fig. 3). 
Comparisons between patients with and 
without HBeAg loss, CVR achievement, and HCC 
development
Because the rate of HBeAg loss was significantly different ac-
cording to the presence of HS, we selected 172 HBeAg-positive 
patients and compared the baseline characteristics between those 
with and without HBeAg loss (Table 2). Patients with HBeAg loss 
showed significantly lower CAP value (median 214.0 vs. 239.0 
dB/m, P=0.013), whereas the proportion of CVR achievement was 
significantly higher in patients with HBeAg loss (97.3 vs. 82.2%, 
P=0.021) (Table 2).
When the study population was stratified according to CVR 
achievement (Table 3) and HCC development (Supplementary Ta-
ble 3), BMI (median 23.3 vs. 24.9 kg/m2), ALT level (median 54 vs. 
66 IU/L), platelet count (median 148×109/L vs. 182×109/L), HBeAg 
table 2. Comparison between patients with and without HBeAg loss among HBeAg-positive patients (n=172)
Variables HBeAg loss (n=37, 21.5%) No HBeAg loss (n=135, 78.5%) P-value
Demographic data
   Age (years) 45.0 (36.5-54.5) 48.0 (40.0-56.0) 0.401
   Male gender 20 (54.1) 81 (60.0) 0.515
   Body mass index (kg/m2) 23.6 (22.1-25.2) 23.4 (20.8-25.6) 0.725
   Diabetes 5 (13.5) 10 (7.4) 0.320
Laboratory data
   Total bilirubin (mg/dL)  0.9 (0.6-1.1) 0.8 (0.6-1.1) 0.344
   Serum albumin (g/dL) 4.1 (3.8-4.3) 4.1 (3.9-4.3) 0.252
   Alanine aminotransferase (IU/L) 59 (44-119) 56 (37-88) 0.088
   Platelet count (109/L) 149 (105-199) 150 (112-211) 0.542
   Prothrombin time (INR) 1.06 (1.00-1.13) 1.02 (0.95-1.09) 0.812
   Total cholesterol (mg/dL) 170.0 (155.0-182.5) 174.0 (154.0-196.5) 0.356
   Low-density lipoprotein (mg/dL) 125.0 (91.0-161.3) 108.5 (87.3-130.3) 0.319
   Alpha-fetoprotein (ng/mL) 5.2 (2.8-10.4) 6.1 (3.6-13.0) 0.479
   HBV DNA (log IU/mL) 6.31 (4.95-7.83) 7.0 (5.8-8.2) 0.130
Liver cirrhosis 5 (13.5) 5 (3.7) 0.248
Transient elastography
   Liver stiffness (kPa) 11.8 (7.7-16.4) 11.9 (7.1-18.8) 0.535
   Liver stiffness >13 kPa 15 (40.5) 63 (46.7) 0.507
   CAP (dB/m) 214.0 (195.0-251.0) 239.0 (204.0-260.0) 0.013
Complete virological response 36 (97.3) 111 (82.2) 0.021
Tenofovir (vs. entecavir) 33 (89.2)/4 (10.8) 119 (88.1)/16 (11.9) 0.562
Variables are expressed as median (interquartile range) or n (%).
HBeAg, hepatitis B e antigen; INR, international normalized ratio; HBV, hepatitis B virus; kPa, kilopascal; CAP, controlled attenuated parameter; dB/m, decibels 
per meter.
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positivity (48.5 vs. 80.6%), HBV DNA level (median 5.66 vs. 8.23 
log IU/mL), CAP value (median 228 vs. 244 dB/m) were signifi-
cantly lower in patients with CVR achievement than in those 
without (all P<0.05), whereas the proportion of liver cirrhosis was 
significantly higher in patients with CVR achievement than in 
those without (51.2 vs. 27.3%, P=0.019). Additionally, patients 
who developed HCC were significantly older (median age 57.0 vs. 
50.0 years) and had a significantly higher proportion of liver cir-
rhosis (92.0% vs. 45.6%) than those who did not (all P<0.001).
Independent predictors of treatment outcomes
First, univariate and subsequent multivariate analyses were per-
formed to identify independent predictors of HBeAg loss among 
HBeAg-positive patients (Table 4). When CAP values were adjust-
ed as continuous variables, higher ALT level (hazard ratio 
[HR]=1.017, 95% confidence interval [CI] 1.008–1.027; P<0.001), 
lower HBV DNA level (HR=0.814, 95% CI 0.687–0.964; 
P=0.017), and lower CAP values (HR=0.991, 95% CI 0.983–
0.999; P=0.026) were independently associated with a higher 
probability of HBeAg loss among HBeAg-positive patients. Fur-
thermore, CAP value was selected as an independent predictor of 
CVR achievement (Table 5, Supplementary Table 4).
When the cutoff value of 238 dB/m was used to define HS (S1-3 
[n=146, 43.7%] vs. S0 [n=188, 56.3%]),22 the presence of HS 
tended to reduce the probability of HBeAg loss (HR=0.494, 95% 
CI 0.233–1.047, P=0.066); however, both CVR achievement and 
HCC development were not significantly associated with HS after 
adjustment (all P>0.1). In addition, when HS was further divided 
as S0-1 (n=259, 77.5%) vs. S2-3 (n=75, 22.5%) using the cutoff 
table 3. Comparison between patients with and without CVR
Variables
Patients with CVR
(n=303, 90.7%)
Patients without CVR
(n=33, 9.3%)
P-value
Demographic data
   Age (years) 51.0 (44.0-57.0) 41.0 (33.0-57.0) 0.069
   Male gender 191 (63.0) 19 (61.3) 0.848
   Body mass index (kg/m2) 23.3 (21.5-25.4) 24.9 (22.7-26.6) 0.033
   Diabetes 23 (7.6) 3 (9.7) 0.721
Laboratory data
   Total bilirubin (mg/dL) 0.9 (0.7-1.1) 0.8 (0.6-1.2) 0.519
   Serum albumin (g/dL) 4.2 (3.9-4.4) 4.1 (4.0-4.3) 0.874
   Alanine aminotransferase (IU/L) 54 (34-91) 66 (48-119) 0.040
   Platelet count (109/L) 148 (110-192) 182 (118-236) 0.044
   Prothrombin time (INR) 1.02 (0.96-1.09) 1.01 (0.94-1.16) 0.770
   Total cholesterol (mg/dL) 172 (151-196) 174 (150-193) 0.923
   Low-density lipoprotein (mg/dL) 112 (92-178) 102 (79.8-135.3) 0.743
   Alpha-fetoprotein (ng/mL) 4.73 (2.68-9.48) 4.1 (2.6-12.5) 0.924
   HBeAg positivity 147 (48.5) 25 (80.6) 0.001
   HBV DNA (log IU/mL) 5.66 (4.25-6.87) 8.23 (6.74-8.23) <0.001
Liver cirrhosis 155 (51.2) 9 (27.3) 0.019
Transient elastography
   Liver stiffness (kPa) 10.9 (7.1-16.8) 11.6 (6.3-16.6) 0.657
   Liver stiffness >13 kPa 121 (39.9) 11 (35.5) 0.629
   CAP (dB/m) 228 (202-253) 244 (214-279) 0.044
Tenofovir (vs. entecavir) 264 (87.1)/39 (12.9) 28 (90.3)/3 (9.7) 0.780
Variables are expressed as median (interquartile range) or n (%).
CVR, complete virological response; INR, international normalized ratio; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; kPa, kilopascal; CAP, controlled 
attenuated parameter; dB/m, decibels per meter.
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value of 269 dB/m,22 S2-3 was not associated with the probability 
of HBeAg loss and HCC development (all P>0.1). S2-3 was, how-
ever, independently associated with a reduced probability of CVR 
achievement (HR=0.676, 95% CI 0.500–0.914, P=0.011).
dISCuSSIon
In this study, around half of the study population with CHB had 
concomitant HS (146 of 334, 43.7%) at the time of initiating AVT. 
During the study period, 303 (90.7%) and 25 (7.5%) patients 
achieved CVR and developed HCC, respectively. Moreover, among 
172 HBeAg-positive patients, 37 (21.5%) experienced HBeAg 
loss. Multivariate analysis indicated that lower CAP value was in-
dependently associated with a higher probability of HBeAg loss 
among HBeAg-positive patients (HR=0.989) and with CVR 
achievement in the entire study population (HR=0.996, P=0.004), 
whereas the probability of HCC development was not significantly 
associated with CAP value (P=0.380). Finally, the cumulative inci-
dence of HBeAg loss among HBeAg-positive patients was signifi-
cantly higher in patients without HS than in those with HS 
(P=0.022, log-rank test).
In accordance with the rising prevalence of fatty liver world-
wide, the prevalence of concomitant HS in chronic viral hepatitis 
and its influence on the natural course or treatment outcomes 
have recently gained medical interest.6 Furthermore, recent potent 
antiviral agents such as entecavir and tenofovir have been report-
ed to suppress viral replication and the progression of liver cirrho-
sis, in of patients treated with AVT.25 Thus, our study naturally fo-
cused on the remaining factors of concomitant HS that could not 
be controlled using antiviral agents. According to previous studies 
in CHB patients, the prevalence of concomitant HS has ranged 
table 4. Independent predictors of HBeAg loss among HBeAg-positive patients
Variables
Univariate Multivariate (adjusting CAP value)
P-value HR (95% CI) P-value
Demographic data
   Age (years) 0.498 - -
   Male gender 0.524 - -
   Body mass index (kg/m2) 0.629 - -
   Diabetes 0.221 - -
Laboratory data
   Total bilirubin (mg/dL) 0.219 - -
   Serum albumin (g/dL) 0.121 0.669 (0.346-1.292) 0.231
   Alanine aminotransferase (IU/L) 0.063 1.017 (1.008-1.027) <0.001
   Platelet count (109/L) 0.342 - -
   Prothrombin time (INR) 0.610 - -
   Total cholesterol (mg/dL) 0.281 - -
   Low-density lipoprotein (mg/dL) 0.309 - -
   Alpha-fetoprotein (ng/mL) 0.571 - -
   HBV DNA (log IU/mL) 0.159 0.814 (0.687-0.964) 0.017
Liver cirrhosis 0.152 2.064 (0.955-4.459) 0.065
Transient elastography
   Liver stiffness (kPa) 0.654 - -
   Liver stiffness >13 kPa 0.694 - -
   CAP (dB/m) 0.021 0.991 (0.983-0.999) 0.026
Tenofovir (vs. entecavir) 0.598 - -
Variables are expressed as median (interquartile range) or n (%).
HBeAg, hepatitis B e antigen; CAP, controlled attenuated parameter; HR, hazard ratio; CI, confidence interval; INR, international normalized ratio; HBV, 
hepatitis B virus; kPa, kilopascal; dB/m, decibels per meter. 
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from 15% to 48.8%.6,26 The prevalence of HS affects 20–46% of 
the general Western and Asian population,12,27 which is not so dif-
ferent from that estimated in CHB patients with HS. In our cohort, 
43.7% of the CHB population had coexisting HS, which is similar 
to the previous prevalence. 
Studies on the interaction between HS and HBV have provided 
controversial results. Pooled data of seven studies found an in-
verse association between HBV DNA levels and fatty liver in HBV 
patients,11 whereas Wong et al. reported a negative association 
between CHB and nonalcoholic fatty liver disease prevalence.28 
Our study found a significant influence of HS on the long-term 
treatment outcomes of AVT in CHB patients; higher CAP values 
were associated with a lower probability of HBeAg loss among 
HBeAg-positive patients. Our results are supported by a recent 
meta-analysis showing that the efficacy of AVT declined in CHB 
patients with HS.10 This study suggested that virological and bio-
chemical responses were significantly different between sub-
groups with and without HS diagnosed using sonography.19 This 
negative effect of HS on HBeAg loss in HBeAg-positive patients 
might be explained by the decreased bioavailability of AVT due to 
fatty liver load and its fatty acid deposits leading to a significant 
loss in contact area between hepatocytes and antiviral agents.29 
In contrast, other studies have indicated that HS would not be 
significantly associated with virological response or HBeAg sero-
conversion.26 Differences in antiviral agents, range of BMI, or di-
agnostic tools for diagnosing HS (TE in our study vs. ultrasonogra-
phy in previous studies) might explain this discrepant result. 
Indeed, TE has been considered a more reliable tool for the diag-
nosis and grading of HS in chronic viral hepatitis.17 
Furthermore, CAP value was selected as an independent nega-
tive predictor of CVR achievement in the entire study population. 
Cell histological changes in fatty liver, such as the nucleus being 
table 5. Independent predictors of complete virological response
Variables
Univariate Multivariate (adjusting CAP value)
P-value HR (95% CI) P-value
Demographic data
   Age (years) 0.001 0.999 (0.987-1.011) 0.838
   Male gender 0.846 - -
   Body mass index (kg/m2) 0.328 - -
   Diabetes 0.818 - -
Laboratory data
   Total bilirubin (mg/dL) 0.250 - -
   Serum albumin (g/dL) 0.156 1.366 (1.014-1.840) 0.040
   Alanine aminotransferase (IU/L) 0.003 0.999 (0.995-1.002) 0.458
   Platelet count (109/L) <0.001 0.998 (0.996-1.000) 0.075
   Prothrombin time (INR) 0.722 - -
   Total cholesterol (mg/dL) 0.223 - -
   Low-density lipoprotein (mg/dL) 0.884 - -
   Alpha-fetoprotein (ng/mL) 0.311 - -
   HBeAg positivity <0.001 0.601 (0.451-0.800) <0.001
   HBV DNA (log IU/mL) <0.001 0.794 (0.738-0.854) <0.001
Liver cirrhosis <0.001 0.957 (0.724-1.265) 0.759
Transient elastography
   Liver stiffness (kPa) 0.782 - -
   Liver stiffness >13 kPa 0.605 - -
   CAP (dB/m) 0.018 0.996 (0.993-0.999) 0.004
Tenofovir (vs. entecavir) 0.808 - -
CAP, controlled attenuated parameter; HR, hazard ratio; CI, confidence interval; INR, international normalized ratio; HBeAg, hepatitis B e antigen; HBV, 
hepatitis B virus; kPa, kilopascal; dB/m, decibels per meter.
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pushed to the periphery, could prevent the interaction between 
the AVT agent and viral nucleic acids and explain the negative 
correlation between CAP value and the probability of CVR 
achievement.30 After adjustment, HBeAg positivity and HBV DNA 
levels were both significantly associated with a lower probability 
of CVR achievement, which has been a well-known disadvan-
tage.4 
Although the clear relation between HCC in HS patients and 
HBV is unclear, many factors, including metabolic factors, that are 
significantly associated with fatty liver, are considered to increase 
the risk of HCC development in HBV-infected patients.9 However, 
fatty liver and CAP value did not influence the risk of HCC devel-
opment in our study. The reason for this discrepancy is unclear, 
but can be explained in part by the proportion of CHB patients 
with accompanying nonalcoholic steatohepatitis with fibrosis pro-
gression. Indeed, although a recent study by Seto et al. showed a 
significant correlation between the degree of liver steatosis and 
fibrosis assessed using TE,12 the association was not significant in 
our study. Although histological information is lacking, the differ-
ent proportions of CHB patients with concomitant insult from fat-
ty liver-related inflammation and fibrosis may have been a factor.11 
Thus, the exact association between steatotic burden and the risk 
of HCC development should be further investigated.
Our study has several advantages that strengthen its clinical im-
plications. First, our study is the first of its kind to comprehensive-
ly analyze the effects of HS on the clinical outcomes of CHB pa-
tients undergoing treatment with potent AVT agents according to 
recent guidelines.4 Thus, our results can be applied to CHB pa-
tients in this era of potent and active AVT. Second, in contrast to 
previous research with subjective ultrasonography assessment of 
steatotic burden, our study adopted TE with CAP to assess HS, 
which has been widely used to assess the degree of fatty liver.12,18 
Finally, we focused on the prognostic clinical influence of accom-
panying HS in CHB patients undergoing AVT beyond the cross-
sectional analysis. Although the influence of dynamic change in 
steatotic burden during AVT could not be assessed, our results 
might provide the rationale to reduce liver steatosis, to increase 
the probability of HBeAg seroconversion for HBeAg-positive pa-
tients. 
Our study also has several limitations. First, although the overall 
sample size was acceptable, the proportion of end points such as 
HCC was relatively small. Thus, the lack of association between 
steatotic burden and the risk of HCC development might stem 
from statistical bias. Indeed, cirrhosis being selected as one of the 
independent predictors of HCC development in our study whereas 
LS value assessed using TE was not may be attributable to the 
small number of patients who developed HCC. Additionally, the 
high proportion of patients with liver cirrhosis (49.1%) and high 
ALT levels at the time of starting AVT, in spite of the exclusion of 
ALT >5× the upper limit of normal, might also have influenced 
our results. Second, our study was limited by the lack of data on 
detailed histological characteristics related to the risk of end-point 
achievement. We do not know whether pure steatotic burden was 
significantly associated with the treatment outcomes or whether 
a combination of steatotic burden and additional characteristics 
such as fibrosis are involved. Lastly, the skewed distribution of 
patients with different steatotic burden might have biased our re-
sults. Owing to the retrospective nature of this study, it was inevi-
table to have more patients with lesser steatotic burden. Likely 
due to the same reason, the results from binary stratification of 
HS using several previous cutoff values were similar, but not con-
sistent with those from continuously expressed CAP values.22
In conclusion, we demonstrated that CAP value was not corre-
lated with HCC development in patients initiated on AVT with en-
tecavir and tenofovir. However, CAP value was negatively corre-
lated with the risk of HBeAg loss among HBeAg-positive patients 
and with CVR achievement in the entire study population.
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